Skip to main content

Thermo Fisher Scientific Remaining performance obligations

  • TMO · NYSE
  • Instruments
  • Life Sciences Tools & Services
  • S&P 500
$700.22+0.11%Close 13 Nov 2026

Remaining performance obligations at Thermo Fisher Scientific came to $29.9B at 26 Sep 2026, up 12.9% from a year earlier.

As Thermo Fisher Scientific reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 30 Oct 2026.

By quarter

$26.9BDec 2023$26.4BMar 2024$25.9BJun 2024$25.3BSep 2024$24.6BDec 2024$24.5BMar 2025$25.0BJun 2025$26.5BSep 2025$27.9BDec 2025$29.4BMar 2026$29.7BJun 2026$29.9BSep 2026
Thermo Fisher Scientific Remaining performance obligations, every reported period
Period endingRemaining performance obligationsChange on a yearFiled
26 Sep 2026$29.9Bup 12.9%30 Oct 2026
27 Jun 2026$29.7Bup 18.6%31 Jul 2026
28 Mar 2026$29.4Bup 19.8%1 May 2026
31 Dec 2025$27.9Bup 13.4%26 Feb 2026
27 Sep 2025$26.5Bup 4.6%31 Oct 2025
28 Jun 2025$25.0Bdown 3.4%1 Aug 2025
29 Mar 2025$24.5Bdown 6.9%2 May 2025
31 Dec 2024$24.6Bdown 8.6%20 Feb 2025
28 Sep 2024$25.3Bdown 5.6%1 Nov 2024
29 Jun 2024$25.9Bup 2.1%2 Aug 2024
30 Mar 2024$26.4Bup 2.2%3 May 2024
31 Dec 2023$26.9Bdown 0.2%22 Feb 2024
30 Sep 2023$26.8Bup 0.8%3 Nov 2023
1 Jul 2023$25.4Bdown 8.3%4 Aug 2023
1 Apr 2023$25.8Bdown 10.5%5 May 2023
31 Dec 2022$27.0Bdown 4.7%23 Feb 2023
1 Oct 2022$26.6Bup 83.6%4 Nov 2022
2 Jul 2022$27.7Bup 104.3%5 Aug 2022
2 Apr 2022$28.8Bup 117.0%6 May 2022
31 Dec 2021$28.3Bup 120.9%24 Feb 2022
2 Oct 2021$14.5Bup 29.8%4 Nov 2021
3 Jul 2021$13.6Bup 35.7%6 Aug 2021
3 Apr 2021$13.3Bup 59.0%7 May 2021
31 Dec 2020$12.8Bup 64.9%25 Feb 2021
26 Sep 2020$11.2Bup 65.1%30 Oct 2020
27 Jun 2020$10.0Bup 41.3%31 Jul 2020
28 Mar 2020$8.4Bup 50.1%1 May 2020
31 Dec 2019$7.8Bup 52.7%26 Feb 2020
28 Sep 2019$6.8Bup 32.0%1 Nov 2019
29 Jun 2019$7.1Bup 38.1%2 Aug 2019
30 Mar 2019$5.6Bup 12.8%3 May 2019
31 Dec 2018$5.1B—27 Feb 2019
29 Sep 2018$5.1B—2 Nov 2018
30 Jun 2018$5.1B—3 Aug 2018
31 Mar 2018$4.9B—4 May 2018

Definition

Revenue under signed contracts that the company has not yet recognised: deferred revenue plus amounts it will invoice and recognise later (ASC 606). Stated at each balance-sheet date. Companies may leave out contracts of a year or less. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.

Other operating KPIs of Thermo Fisher Scientific: Organic revenue (change on a year) · Product revenues · Service revenues · Consumables revenue · Instruments revenue · Clinical research revenue · Research and safety market channel revenue · Pharma services revenue · Biosciences revenue · BioProduction revenue · Chromatography and mass spectrometry revenue · Electron microscopy revenue · Genetic sciences revenue · Laboratory products revenue · Healthcare market channel revenue · Chemical analysis revenue · Clinical diagnostics revenue · ImmunoDiagnostics revenue · Transplant diagnostics revenue · Microbiology revenue · Laboratory Products and Biopharma Services revenue · Life Sciences Solutions revenue · Analytical Instruments revenue · Specialty Diagnostics revenue · financial statements

Every KPI and segment of TMO, in the terminal.

Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.